Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Frederic Baron, MD PhD, Marian Stevens-Kroef, PhD, Giovanna Meloni, MD, Petra Muus, MD PhD, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD PhD, Xavier Thomas, MD PhD, Radovan Vrhovac, MD PhD, Giorgina Specchia, MD, Francois Lefrere, Sr., MD, Simona Sica, Marco Mancini, MD, Adriano Venditti, MD, Anne Hagemeijer, MD, Joop H. Jansen, PhD, Sergio Amadori, MD, Theo de Witte, MD, Roelof Willemze, MD PhD, Stefan Suciu, PhD

Blood (2016) 128 (22): 2847.

https://doi.org/10.1182/blood.V128.22.2847.2847

Published: 2016

Journal Articles

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Blood (2016) 128 (22): 2288.

https://doi.org/10.1182/blood.V128.22.2288.2288

Published: 2016

Journal Articles

Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups

Blood (2014) 124 (21): 619.

https://doi.org/10.1182/blood.V124.21.619.619

Published: 2014

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Safaa M. Ramadan, MD, PhD, Stefan Suciu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Roelof Willemze, MD, PhD, Sergio Amadori, Theo de Witte, MD, Bob Lowenberg, MD, PhD, Petra Muus, MD, PhD, Boris Labar, MD, PhD, Liv Meert, Gaetan de Schaetzen, Giovanna Meloni, MD, Giuseppe Leone, MD, Marco Vignetti, Franco Mandelli, MD, Frederic Baron, MD, PhD, Jean-Pierre Marie, MD

Blood (2013) 122 (21): 829.

https://doi.org/10.1182/blood.V122.21.829.829

Published: 2013

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC

Blood (2011) 118 (21): 257.

https://doi.org/10.1182/blood.V118.21.257.257

Published: 2011

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen (AraC and idarubicin) in Patients with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS):Phase I Results of An Ongoing Phase I/II Study of the EORTC-LG and GIMEMA(EORTC GIMEMA 06061/AML-14A trial)

Roelof Willemze, MD, PhD, Petra Muus, MD, PhD, Stijn J.M. Halkes, Giovanna Meloni, MD, Stefan Suciu, Liv Meert, Jocelyne Flament, Matthias Karrasch, Marco Vignetti, Sergio Amadori, MD, Theo M. de Witte, MD, Jean-Pierre Marie, MD

Blood (2011) 118 (21): 2610.

https://doi.org/10.1182/blood.V118.21.2610.2610

Published: 2011

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of Low Dose IL-2 Maintenance,

Blood (2011) 118 (21): 3612.

https://doi.org/10.1182/blood.V118.21.3612.3612

Published: 2011

Journal Articles

Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation.

Tom Lodewyck, MD, Machteld Oudshoorn, PhD, Bronno van der Holt, PhD, Eefke Petersen, MD, PhD, Eric Spierings, PhD, Peter A. Von Dem Borne, MD, PhD, Anton Schattenberg, MD, PhD, Wil Allebes, PhD, Ellen Meijer, MD, PhD, Marlies Groenendijk-Sijnke, Lucia Duinhouwer, Roelof Willemze, MD, PhD, Leo F. Verdonck, MD, PhD, Bob Lowenberg, MD, PhD, Jan J. Cornelissen, MD, PhD

Blood (2009) 114 (22): 1196.

https://doi.org/10.1182/blood.V114.22.1196.1196

Published: 2009

Journal Articles

Potent Alloreactive Effector T Cells Cause Limited Damage to Non-Hematopoietic Tissues Under Non-Inflammatory Conditions, Despite Proper Expression of the Relevant Target Antigens.

Boris van der Zouwen, MD, Alwine B. Kruisselbrink, Peter A. Von Dem Borne, MD PhD, Roelof Willemze, MD PhD, J.H. Frederik Falkenburg, MD PhD, Inge Jedema, PhD

Blood (2009) 114 (22): 2454.

https://doi.org/10.1182/blood.V114.22.2454.2454

Published: 2009

Journal Articles

Treatment with Tyrosine Kinase Inhibitors May Impair the Potential Curative Effect of Allogeneic Stem Cell Transplantation.

Inge Jedema, PhD, Linda van Dreunen, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2009) 114 (22): 857.

https://doi.org/10.1182/blood.V114.22.857.857

Published: 2009

Journal Articles

Value of Low Dose IL-2 as Maintenance Following Consolidation Treatment or Autologous Transplantation in Acute Myelogenous Leukemia (AML) Patients Aged 15-60 Years Who Reached CR After High Dose (HD-AraC) Vs Standard Dose (SD-AraC) Cytosine Arabinoside During Induction: Results of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups.

Blood (2009) 114 (22): 791.

https://doi.org/10.1182/blood.V114.22.791.791

Published: 2009

Journal Articles

Leukemic CD52 Negative Subclones Due to Defective Glycophosphatidyl-Innositol Anchoring Are Common in Acute Precursor B Lymphoblastic Leukemia, Escape Alemtuzumab Therapy, but Display Increased Sensitivity to Rituximab Mediated Complement Dependent Cytotoxicity: a Mechanistic Rationale for Antibody Combination Therapy.

Bart Nijmeijer, PhD, Marianke LJ Van Schie, Henriette maria Goselink, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2009) 114 (22): 835.

https://doi.org/10.1182/blood.V114.22.835.835

Published: 2009

Journal Articles

Extracellular Domains of CD8a and β Subunits Are Required and Sufficient for HLA Class I Restricted Helper Activity of TCR-Engineered CD4 + T Cells.

Marleen M van Loenen, MSc, Renate S. Hagedoorn, MSc, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, Mirjam H.M. Heemskerk, PhD

Blood (2009) 114 (22): 3574.

https://doi.org/10.1182/blood.V114.22.3574.3574

Published: 2009

Journal Articles

Optimization of the HA-1-Specific T Cell Receptor for Gene Therapy of Hematological Malignancies.

Marleen M van Loenen, MSc, Renate S. Hagedoorn, MSc, Renate de Boer, BSc, Esther M. van Egmond, BSc, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, Mirjam H.M. Heemskerk, PhD

Blood (2009) 114 (22): 4093.

https://doi.org/10.1182/blood.V114.22.4093.4093

Published: 2009

Journal Articles

Collateral Damage: a Mechanism for Hematopoiesis-Restricted Mhag-Specific T Cells to Play a Role in the Effector Phase of GvHD.

Boris van der Zouwen, MD, Alwine B. Kruisselbrink, Peter A. Von Dem Borne, MD, PhD, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, Inge Jedema, PhD

Blood (2009) 114 (22): 3552.

https://doi.org/10.1182/blood.V114.22.3552.3552

Published: 2009

Journal Articles

Human T Cells with Distinct Specificities Mediate Graft-Versus-Leukemia Reactivity and Xenogeneic Graft-Versus-Host Disease in a NOD/Scid Mouse Model for Human Acute Leukemia.

Sanja Stevanovic, Bart Nijmeijer, PhD, Marianke LJ Van Schie, Roelof Willemze, MD, PhD, Marieke Griffioen, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2009) 114 (22): 1330.

https://doi.org/10.1182/blood.V114.22.1330.1330

Published: 2009

Journal Articles

Identification of Four New HLA Class II Restricted Minor Histocompatibility Antigens Contributing to Graft Versus Leukemia Reactivity.

Anita N. Stumpf, Edith D. van der Meijden, Cornelis A.M. van Bergen, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, Marieke Griffioen, PhD

Blood (2008) 112 (11): 3247.

https://doi.org/10.1182/blood.V112.11.3247.3247

Published: 2008

Journal Articles

Detailed Analysis of CD8+ T Cell Immunity and Identification of a Novel Minor Histocompatibility Antigen Contributing to Graft-Versus- Leukemia Reactivity.

Marieke Griffioen, PhD, M. Willy Honders, Edith D. van der Meijden, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2008) 112 (11): 3250.

https://doi.org/10.1182/blood.V112.11.3250.3250

Published: 2008

Journal Articles

HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1 Specific T Cell Responses Showing Immunogenicity of All HLA-DPB1 Alleles

Caroline E. Rutten, M.D., Simone A.P. van Luxemburg-Heijs, Edith D. van der Meijden, Marieke Griffioen, PhD, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2008) 112 (11): 3504.

https://doi.org/10.1182/blood.V112.11.3504.3504

Published: 2008

NARROW

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation.

Potent Alloreactive Effector T Cells Cause Limited Damage to Non-Hematopoietic Tissues Under Non-Inflammatory Conditions, Despite Proper Expression of the Relevant Target Antigens.

Treatment with Tyrosine Kinase Inhibitors May Impair the Potential Curative Effect of Allogeneic Stem Cell Transplantation.

Extracellular Domains of CD8a and β Subunits Are Required and Sufficient for HLA Class I Restricted Helper Activity of TCR-Engineered CD4 + T Cells.

Optimization of the HA-1-Specific T Cell Receptor for Gene Therapy of Hematological Malignancies.

Collateral Damage: a Mechanism for Hematopoiesis-Restricted Mhag-Specific T Cells to Play a Role in the Effector Phase of GvHD.

Human T Cells with Distinct Specificities Mediate Graft-Versus-Leukemia Reactivity and Xenogeneic Graft-Versus-Host Disease in a NOD/Scid Mouse Model for Human Acute Leukemia.

Identification of Four New HLA Class II Restricted Minor Histocompatibility Antigens Contributing to Graft Versus Leukemia Reactivity.

Detailed Analysis of CD8+ T Cell Immunity and Identification of a Novel Minor Histocompatibility Antigen Contributing to Graft-Versus- Leukemia Reactivity.

HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1 Specific T Cell Responses Showing Immunogenicity of All HLA-DPB1 Alleles

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only